secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001437749-26-013037
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed: neflamapimod increases basal forebrain volume in DLB Phase 2b MRI analysis
--------------------------------------------------------------------------------

- At week 16, right BF volume increased 3.5% with neflamapimod vs -4.2% with placebo (p=0.028).
- Right BF to DMN functional connectivity improved 46% during 32-week extension (p=0.014).
- Improvement in functional connectivity correlated with CDR-SB reduction (p=0.027, r²=0.43).
- Company plans to start Phase 3 trial in DLB later this year, subject to financing.
- Data presented at 2026 AAN Annual Meeting by Amsterdam UMC; blinded analysis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926013037/0001437749-26-013037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926013037/crvo20260422_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-013037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer